Model BTX 1801 - Antimicrobial Gel for Post Surgical Infections

BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). Botanix Pharmaceutical’s research to date shows synthetic cannabidiol rapidly kills MRSA within 10 minutes of exposure by a novel mechanism of action, and without allowing resistance to develop. BTX 1801 is initially focused on preventing surgical site infections (SSIs), which are caused by bacteria that get in through surgery incisions and threaten millions of lives every year. Botanix plans to test the capabilities of synthetic cannabinoid for fighting antibiotic resistance more broadly – a major global issue in healthcare – and to develop a novel platform product for multiple human and animal health applications.